Mitochondrial antiviral signaling (MAVS) is a key adaptor in cellular antiviral innate immunity. We previously identified poly(C)-binding protein 2 (PCBP2) as a feedback inhibitor of MAVS that facilitates its degradation after viral infection, but little is known about the regulatory potential of poly(C)-binding protein 1 (PCBP1), which highly resembles PCBP2. Here we report that PCBP1 mediates housekeeping degradation of MAVS using the same mechanism as PCBP2 employs. Overexpression of PCBP1 impairs MAVS-mediated antiviral responses, while knockdown of PCBP1 exerts the opposite effect. The suppression is due to PCBP1-induced MAVS degradation. We observe that PCBP1 and PCBP2 show synergy in MAVS inhibition, but their expression patterns are distinct: PCBP1 is stably and abundantly expressed, while PCBP2 shows low basal expression with rapid induction after infection. Individual knockdown and subcellular fractionation analyses reveal that unlike the postinfection inhibitor PCBP2, PCBP1 continuously eliminates cellular MAVS. Our findings unravel a critical role of PCBP1 in regulating MAVS for both finetuning the antiviral immunity and preventing inflammation.
Introduction
Cellular antiviral innate immunity involves the detection of viral double-stranded RNA by cytoplasmic receptors including retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) [1, 2] , which interact with the adaptor mitochondrial antiviral signaling (MAVS, also known as virus-induced signaling adaptor/interferon (IFN)-β promoter stimulator 1/caspase activation and recruitment domain adaptor inducing IFN-β) [3] [4] [5] [6] . MAVS contains an N-terminal caspase activation and recruitment domain required for receptor binding and a C-terminal transmembrane domain (TM) that targets the protein to the mitochondria and peroxisomes [7, 8] . At the receptor-proximal level, MAVS serves as a nexus to integrate the signaling of RIG-I-like receptors (RLRs) and mediate the downstream TANK-binding kinase 1 (TBK1)/IκB kinase ε activation [9] . These kinases liberate transcription factors such as nuclear factor κB (NF-κB) and IFN regulatory factor 3/7, leading to the induction of type I IFNs and pro-inflammatory cytokines [10, 11] . Once secreted, type I IFNs rapidly induce multiple IFN-stimulated genes [12, 13] that orchestrate an antiviral state in the cells [14] . Due to its prominent role in propagating antiviral signaling [15, 16] , MAVS is subject to meticulous modulations by different proteins [17] , which fine-tune the cellular responses over the course of viral infection [18] [19] [20] [21] .
Previously, we identified both PCBP1/PCBP2; also known as α-complex protein 1/2 or heterogeneous nuclear ribonucleoprotein E1/2 as MAVS-interacting candidates in a yeast two-hybrid screen, and delineated a novel cascade for MAVS degradation by the PCBP2-AIP4 (Atrophin 1-interacting protein 4, also known as Itchy homolog E3 ubiquitin ligase) axis [22] . Of note, PCBP1 is highly homologous to PCBP2 and frequently collaborates with PCBP2 in various cellular processes [23] [24] [25] [26] [27] . However, it is still unknown whether PCBP1 holds an impact on cellular antiviral immunity.
Here we report that PCBP1 negatively modulates cellular antiviral signaling by restricting MAVS abundance. It promotes housekeeping degradation of MAVS regardless of the infection signal, through interactions with both MAVS and AIP4. Our findings highlight the inhibitory role for PCBP1 in manipulating both inflammation and innate antiviral immune responses.
Results

PCBP1 inhibits MAVS-mediated activation of IRF3 and NF-κB
To address the potential role of PCBP1 in regulating cellular antiviral signaling, we examined the effects of PCBP1 overexpression on virus-triggered reporter gene activation. Sendai virus (SeV)-induced IFN-β, ISRE and NF-κB activation was inhibited by PCBP1 in a dosedependent way in 293 cells ( Figure 1A ), implicating a negative role for PCBP1 in SeV-induced antiviral responses. Next we used both 293 and 293-TLR3 cells (293 cells stably expressing Toll-like receptor 3) to clarify the involvement of PCBP1 in separate pathways, as the synthetic viral double-stranded RNA analog poly(I:C) can only activate IFN-β in TLR3-deficient 293 cells by transfection through the RLR-MAVS pathway; in contrast, 293-TLR3 cells incubated with poly(I:C) show robust IFN-β induction. We found that PCBP1 suppressed transfected but not incubated poly(I:C)-triggered IFN-β activation ( Figure 1B) , suggesting that it specifically influences intracellular double-stranded RNA signaling. Consistent with that, SeV-and poly(I:C)-triggered secretion of type I IFNs was crippled in cells expressing PCBP1 ( Figure 1C) . Moreover, PCBP1 dispelled SeV-, Newcastle disease virus (NDV)-and transfected poly(I:C)-induced IRF3 dimerization ( Figure 1D ), which is a hallmark of IRF3 activation [28] . Collectively, these data demonstrate that PCBP1 acts as an inhibitor within the intracellular antiviral pathway.
We coexpressed PCBP1 and components of the cel- 
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npg lular antiviral pathway to see if PCBP1 also functions at the MAVS level as PCBP2 does [22] . IFN-β induction by MAVS and its upstream RLRs was inhibited by PCBP1, but that by TBK1 and IRF3 was unaffected (Supplementary information, Figure S1A ). Measurements of vesicular stomatitis virus (VSV) titers in 293 cells showed that PCBP1 reversed the suppression of viral replication by RIG-I-N (amino acid 1-284), MDA5-N (amino acid 1-206) and MAVS, but not by TBK1 (Supplementary information, Figure S1C ). Meanwhile, TRIF-induced reporter activation and IRF3 dimerization were intact (Supplementary information, Figure S1A and S1B). Therefore, PCBP1 selectively inhibits RLR-mediated type I IFN induction at the point of MAVS.
Knockdown of PCBP1 augments cellular antiviral responses
To validate a repression effect for endogenous PCBP1, we used a PCBP1-specific RNAi plasmid [27] to reduce its expression in cells. PCBP1 suppression ( Figure 2A ) correlated with potentiated IFN-β induction in SeV-and transfected poly(I:C)-stimulated 293 cells ( Figure 2B ). Consistently, PCBP1 suppression in HeLa cells promoted IFN-β induction by transfected but not incubated poly(I:C) ( Figure 2C ), indicating its selectivity for the intracellular antiviral pathway. Moreover, PCBP1 depletion prompted an increase in type I IFN production in cells stimulated with SeV or poly(I:C) transfection ( Figure  2D ). Moreover, PCBP1 knockdown resulted in boosted IFN-β induction triggered by MAVS, RIG-I and MDA5, but not by TRIF, TBK1 or IRF3 (Supplementary information, Figure S1D ), and the magnitude of VSV replication declined upon a drop in the level of PCBP1 (Supplementary information, Figure S1E ). In summary, these results indicate that PCBP1 negatively regulates MAVSmediated antiviral signaling.
Interaction of PCBP1 with MAVS
Consistent with a previously identified interaction in the yeast 2-hybrid screen, coimmunoprecipitation experiments in 293 cells revealed that PCBP1 interacted with MAVS, RIG-I and MDA5, but not TRIF or TBK1 (Supplementary information, Figure S2A ). In particular, MAVS C-terminus (amino acid 360-540) was both necessary and sufficient for PCBP1 binding, whereas neither the caspase activation and recruitment domain nor the proline-rich region was required (Supplementary information, Figure S2B ). Critically, sending MAVS to the endoplasmic reticulum membrane with VAMP-2-TM [3] largely impaired its association with PCBP1, while mi- Figure S2C ). These data point to a conclusion that a structural or topological element (or both) unique to the correctly positioned MAVS is important for the interaction.
PCBP1 mediates MAVS degradation via the E3 ubiquitin ligase AIP4
The above results showed functional similarities of PCBP1 and PCBP2 in MAVS inhibition, thus we tested if PCBP1 also mediates MAVS degradation. As we expected, the amount of MAVS protein was much lower upon PCBP1 overexpression while its mRNA remained stable ( Figure 3A ). Treatment with a proteasome inhibitor MG-132 considerably blocked the protein reduction, while a lysosome inhibitor NH 4 Cl showed little effect ( Figure 3A , upper panel). The finding indicates that PCBP1, similar to PCBP2, causes proteasomal degradation of MAVS. As a further proof, PCBP1 led to Lysine 48 (K 48 )-linked polyubiquitination of MAVS (Supplementary information, Figure S3A ).
Previously, we identified AIP4 as the E3 ubiquitin ligase for MAVS. In fact, it was also recruited by PCBP1 (Supplementary information, Figure S3B ) to MAVS-containing complex and enhanced MAVS ubiquitination in the presence of MG-132 ( Figure 3B ). AIP4 overexpression augmented PCBP1-mediated MAVS degradation ( Figure 3C ) while its knockdown could minimize SeVinduced MAVS ubiquitination ( Figure 3D ). Critically, AIP4(C 830 A), a ligase-deficient version that interacted with PCBP1 (Supplementary information, Figure S3B ), failed to synergize with PCBP1 on MAVS degradation ( Figure 3C ) and even blocked MAVS ubiquitination (Figure 3B) . These findings stress the importance of an intact ligase activity of AIP4 during MAVS degradation. On the other hand, sequence alignment revealed that a welldefined AIP4 docking site in PCBP2 is highly conserved in PCBP1 (PASSPV, amino acid [187] [188] [189] [190] [191] [192] Figure  S3B ) and hindered AIP4-mediated MAVS ubiquitination ( Figure 3B ), highlighting the importance of PCBP1 as an adaptor between AIP4 and MAVS. Specifically, loss of AIP4 abrogated the ability of PCBP1 to suppress IFN-β induction by MAVS and RIG-I, but had minimal effect on RNF125 that independently leads to RIG-I and MAVS degradation [29] (Supplementary information, Figure S3C ). Collectively, these results suggest that both PCBP1 and PCBP2 facilitate the degradation of MAVS by AIP4.
The synergy of PCBP1 and PCBP2 in regulating MAVS
Now that both PCBPs utilize the same mechanism to regulate MAVS, it is intriguing to find out whether there is a competition or antagonism in between. We investigated the combinatorial actions of PCBP1 and PCBP2 and found that they synergized to inhibit MAVS-induced IFN-β activation in reporter assays, accompanied by enhanced MAVS degradation ( Figure 4A ). The residual activity of MAVS upon individual PCBP overexpression was almost entirely lost by coexpression of both, reflected by a drop in MAVS-induced type I IFN production ( Figure 4B ). Furthermore, coexpression of the two proteins resulted in exaggerated suppression on SeV-and poly(I:C)-triggered IFN-β induction ( Figure 4C) . In all these conditions, PCBP1 and PCBP2 showed a coordinated fashion to inhibit MAVS.
Different expression patterns of PCBP1 and PCBP2 during viral infection
To address their possible modes of action under physiological conditions, we assessed the distribution of PCBP1 and PCBP2 in mouse organs to see if there was a difference. However, in agreement with a previous report [23] , both PCBPs were ubiquitously expressed (Supple- Figure S4A ). Then we examined their levels both in resting cells and from stimulated cells. Interestingly, an obvious difference was observed. PCBP1 was stably and abundantly expressed while PCBP2 was robustly induced after stimulation (Figure 5A) . Similar results were obtained in SeV-infected A549 (human lung adenocarcinoma epithelial cell line), HT1080 (human fibrosarcoma cell line) and U937 (human leukemic monocyte lymphoma cell line) cells ( Figure  5B ), indicative of a pervasive expression pattern for the PCBPs in response to viral infection.
Housekeeping degradation of MAVS by PCBP1 in vivo
The expression difference between PCBP1 and PCBP2 is likely related to their physiological functions. To test this, we investigated the effect of each PCBP on MAVSmediated signaling throughout the infection. First, we confirmed continuous proteasome-dependent degradation of MAVS in both resting and SeV-infected cells, as indicated by its enrichment in the presence of MG-132 (Supplementary information, Figure S4B) . Importantly, the level of MAVS increased upon PCBP1 knockdown in untreated cells, but barely changed when PCBP2 was separately silenced (Figure 6A, left) . By contrast, MAVS degradation after SeV infection was mostly reversed by PCBP2 knockdown while modestly affected by PCBP1 depletion (Figure 6A, left) . Similar effects were observed in SeV-infected HeLa cells ( Figure 6A, right) . These data confirmed that PCBP2 is a feedback inhibitor while PCBP1 plays a "housekeeping" role. Consistently, the phosphorylation level of IRF3, another hallmark of MAVS activation [30] , correlated with the regulatory effects of PCBP1 and PCBP2 after infection ( Figure 6A ). Further evidence was obtained from both reporter assays ( Figure 6B ) and VSV plaque assays ( Figure 6C ), in support of a housekeeping effect for PCBP1 on MAVSmediated antiviral responses.
As a prerequisite for regulation, endogenous interaction between PCBP1 and MAVS was detected in 293 cells, regardless of the infection signal ( Figure 7A ). As npg an independent means of assessing an in vivo association, HeLa cells were fractionated to separate cytosol, nuclei and mitochondria, which were distinguished by Caspase-3, Histone H3 and COX IV, respectively. A small but constant portion of PCBP1 was traced in the mitochondrial fraction both before and after infection; by contrast, PCBP2 only started to emerge at mitochondria after 4 h of SeV infection ( Figure 7B ). Double-labeling immunofluorescence studies further confirmed that PCBP1 co-localized with MAVS well before infection ( Figure 7C ). These data support a preexisting association between endogenous PCBP1 and MAVS, compared to an inducible one for PCBP2 and MAVS. Taken together, we conclude that PCBP1 plays a housekeeping role in vivo to negatively modulate MAVS-mediated antiviral immune responses.
Discussion
RIG-I-like receptors play a major role in sensing RNA virus infection and enlist the adaptor MAVS to initiate and modulate antiviral immunity [31] . MAVS is reported to reside on the outer membranes of the mitochondria and peroxisomes [8, 32] where it signals rapid induction of antiviral cytokines including type I IFNs. A tight MAVS regulation is essential to prevent unwarranted responses or even inflammation [33] . The regulation occurs at various levels ranging from complex formation to posttranslational modifications [34] , among which ubiquitination and degradation by the proteasome pathway have been frequently reported [22, 29, 35, 36] .
Following the study on PCBP2 [22] , we here characterized PCBP1 as another negative regulator in cellular antiviral signaling through MAVS degradation. The expression patterns of PCBP1 and PCBP2 support the regulation model we proposed ( Figure 7D ): at the steady phase, MAVS is constantly restricted by PCBP1 to prevent spontaneous activation of the immune responses. Upon viral infection, rapidly boosted signaling turns in favor of positive signal amplification and numerous IFNstimulated genes (including PCBP2) are induced (the active phase). After that, PCBP2 serves as part of the negative feedback loop to shut down MAVS signaling (the terminal phase).
As expected, PCBP1 and PCBP2 adopt the same mechanism to promote MAVS degradation (Figure 3 ). This result conforms to our previous report that the "WB2" motif of PCBP2 is a prerequisite for AIP4 binding [22] , since a highly conserved motif in PCBP1 is also indispensible for AIP4 recruitment ( Figure 3C and Supplementary information, Figure S3B ). As such, it appears that the homology in sequence could not be fortuitous, as the PCBP1 locus was reported as the retrotransposition product of a minor PCBP2 splicing variant [37] . Also, the synergy of PCBP1 and PCBP2 we observed ( Figure  4 ) is consistent with their complementary functions reported before [25-27, 38, 39] .
The present study demonstrates that PCBP1 holds a distinct role in vivo compared to PCBP2 in regulating cellular antiviral signaling, reflected by their different expression patterns, including: (1) the basal level of PCBP1 is much higher than that of PCBP2; and (2) viral infection triggers a sharp increase in PCBP2 abundance without affecting the overall amount of PCBP1 (Figure 5) . The unique property of PCBP1 was observed in knockdown studies that point to a housekeeping role for PCBP1 at the quiescent state ( Figure 6 ). This specificity may serve as another sound piece of evidence for divergent physiological functions of the two proteins as reported elsewhere [40] [41] [42] [43] .
Our investigation extends the multiple capacity of PCBP1 [43, 44] as an E3 ubiquitin ligase adaptor for housekeeping degradation of MAVS [45, 46] . Besides, PCBP1 displays some regulatory effects after viral infection ( Figures 3D and 6) . In either case, the engagement of PCBP1 is crucial because of one thing, effective suppression of IFN-α/β may only be possible with the concerted actions of several suppressors, and for the other, unlike those stimulus-triggered inhibitors including PCBP2 [6, 22, 35, [47] [48] [49] [50] [51] [52] [53] , PCBP1 may serve to tune the threshold for initiation of signal transduction by restricting MAVS at basal conditions [54, 55] . The latter feature of PCBP1 is of special importance in preventing various inflammatory disorders caused by unwanted IFN [33, [56] [57] [58] as a result of possible activities of excessive MAVS. On the other side, MAVS degradation by PCBP2 in those infected cells may seem rather counterproductive for self-protection. Fortunately, PCBP2 belongs to the postinfection inhibitors whose expression is only induced by an infection signal. That said, PCBP2 is expressed at such a low level before stimulation that it can hardly hamper the initiation of proper antiviral responses, but instead functions as a delayed regulator upon induction.
In conclusion, our studies uncover an important role for PCBP1 in immune modulation through housekeeping degradation of MAVS. The finding that both PCBPs punctually fine-tune the activity of MAVS not only highlights the pleiotropic effects of poly(C)-binding proteins, but also implicates an evolutionarily non-redundant function for PCBP1 compared to PCBP2.
Materials and Methods
Plasmids
Mammalian expression plasmids for Flag-and HA-tagged PCBP1, HA-RNF125 and Myc-ubiquitin (Ub) were constructed by standard molecular biology techniques. PCBP1 (S 190 A/P 191 A) was generated using the QuickChange Site-directed Mutagenesis Kit (Stratagene) with the following primers: 5′-G CCC ATG CCG GCC AGC GCC GCA GTC ATC TGC GCG GGC G-3′ and 5′-C GCC CGC GCA GAT GAC TGC GGC GCT GGC CGG CAT GGG C-3′. All constructs were verified by sequencing. HAUb(K 48 ) and HA-Ub(K 63 ) were kindly provided by Dr HongBing Shu (Wuhan University, Wuhan, China). Flag-tagged MAVS (VAMP-2-TM) and MAVS (Bcl-xL-TM) were kind gifts from Dr Zhijian J Chen (University of Texas Southwestern Medical Center, Dallas, USA). Other plasmids were previously described [22] .
Reagents
MG-132 was purchased from Calbiochem. PCBP1 antiserum was generated by immunizing mice with a recombinant His 6 -PCBP1 protein produced in E. coli, at Animal Facility, Institute of Genetics & Developmental Biology, Chinese Academy of Sciences, China. Viruses and other reagents were previously described [22, 59] .
Cell culture, transfection, viral infection and treatment
U937 cells were grown in a 5% CO 2 humidified atmosphere in RPMI1640 (Gibco) with penicillin-streptomycin (Gibco) and 10% fetal bovine serum (Hyclone). Other cells were maintained in Dulbecco's modified Eagle medium (Gibco) with 10% fetal bovine serum and antibiotics. Transient transfection was carried out by the standard calcium phosphate precipitation method. Poly(I:C) (1 µg/ ml) was transfected using GenEscort II (Wisegen) according to the manufacturer's instructions. One hour later, cells were rinsed and cultured in fresh medium for the indicated times. Cycloheximide (100 mg/ml), poly(I:C) (10 µg/ml), MG-132 (20 mM) and NH 4 Cl (20 mM) were applied to culture medium at the indicated concentrations.
Luciferase (Luc) reporter assay
Cells (1 × 10 5 ) were transfected with 100 ng of a Luc reporter gene, 50 ng of pRL-SV40-Renilla (Promega) as an internal control and the indicated expression vectors for 24 h. Reporter gene activity was analyzed using the Dual-Luciferase Reporter 1000 Assay System (Promega) and measured with a TD-20/20 Luminometer (Turner Designs) according to the manufacturers' instructions. Three independent experiments were carried out in duplicate. Error bars represent the mean standard deviations (mean ± SD).
Protein extraction, immunoprecipitation, western blot and Native polyacrylamide gel electrophoresis
Cells were lysed in cold lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 12.5 mM β-glycerophosphate, 1.5 mM MgCl 2 , 2 mM ethylene glycol tetraacetic acid, 10 mM NaF, 1 mM Na 3 VO 4 and 2 mM dithiothreitol) containing protease inhibitors. Immunoprecipitation was carried out in lysates with 20 µl of Protein A Sepharose (Amersham Biosciences) and 1 µg of the indicated antibody at 4 °C for 4 to 12 h with constant agitation. Following three washes in cold lysis buffer or phosphate-buffered saline, samples were eluted with 2 × SDS sample buffer by boiling at 99 °C for 10 min. Western blot was carried out by standard procedures; proteins were visualized with an Odyssey Two-Color Infrared Imaging System (LI-COR Biosciences, USA) according to the manufacturer's instructions.
Native gel electrophoresis and IRF3 dimerization assays were carried out as described previously [22] . Briefly, lysates were mixed with 2× Native sample buffer (0.125 mM Tris-HCl, pH 6.8, 30% glycerol and 2% deoxycholate) before loading and electrophoresis at 25 mA for 1 h on ice.
Type I IFN bioassay
Type I IFN activity was measured as previously described [22] .
RNA interference
Double-stranded oligonucleotides targeting human PCBP1 (5′-GGG AGA GTC ATG ACC ATT C-3′ [27] ) were cloned into the pSuper.Retro RNAi plasmid (Oligoengine Inc.). PCBP2 and AIP4 RNAi plasmids were previously described [22] . For silencing experiments, cells (5 × 10 5 ) were transfected with 3 µg of RNAi plasmids for 48 h prior to further treatment.
VSV plaque assay
293 cells (1 × 10 5 ) were transfected with the indicated expression plasmids for 24 h before infection with VSV in serum-free medium for 1 h. Cells were rinsed and incubated in fresh medium for 23 h. Proper dilutions of the medium containing VSV were inoculated onto confluent monolayer of BHK21 cells for 1 h before fresh medium containing 2% methylcellulose was added for 60 h. Cells were fixed in 4% formaldehyde and stained with 0.2% crystal violet dissolved in 20% methanol. Plaques were counted, averaged and multiplied by the dilution rates for VSV titers measured in plaque forming units per ml.
Immunofluorescence microscopy
Cells on coverslips were fixed in cold methanol for 15 min. After three washes in phosphate buffered saline, cells were blocked in phosphate buffered saline containing 5% bovine serum albumin for 30 min, and incubated with mouse α-PCBP1 and rabbit α-MAVS primary antibodies in phosphate buffered saline containing 3% bovine serum albumin for 2 h at 37 °C. After three washes, cells were incubated with FITC (fluorescein isothiocyanate)-conjugated α-mouse and TXRD-conjugated α-rabbit secondary antibodies (Imgenex) for 1 h at 37 °C and then with DAPI (4′,6-Diamidino-2-phenylindole, Roche) for 15 min. The coverslips were washed extensively and mounted onto slides. Imaging of the cells was carried out using an Olympus BX51 microscope under a ×100 oil objective.
RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen). After reverse transcription with oligo(dT) primer using a RevertAid First Strand cDNA Synthesis Kit (Fermentas), aliquots of products were subject to standard PCR. Gene-specific primer sequences are as follows: PCBP1, 5′-GGA TGC CGG TGT GAC TGA AAG-3′ and 5′-TTA CAC CCG CCT TTC CCA ATC-3′; MAVS, 5′-CCG TTT GCT GAA GAC AAG-3′ and 5′-CTA GTA GCT CTG GTA GAC AGA GGC-3′; HPRT, 5′-CTG GCG TCG TGA TTA GTG ATG-3′ and 5′-TAT CCA ACA CTT CGT GGG GTC-3′.
Subcellular fractionation
HeLa cells were rinsed and lysed in cold homogenization buffer (buffer H: 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , 0.2 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol and protease inhibitors). The homogenate (S0) was centrifuged at 500× g for 10 min and the pellet was resuspended in buffer H as crude nuclei (P1). The supernatant was centrifuged at 5 000× g for 10 min to precipitate crude mitochondria (P5).
Statistics
The student's t-test was used for a comparison of two independent treatments. For all tests, a P value < 0.05 was considered significant (*) while P < 0.01, very significant (**).
